Comparative Pharmacology
Head-to-head clinical analysis: SULF 10 versus SULFACEL 15.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULF 10 versus SULFACEL 15.
SULF-10 vs SULFACEL-15
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfacetamide inhibits bacterial dihydropteroate synthase, blocking folate synthesis and thereby nucleic acid production.
Sulfacetamide inhibits bacterial dihydropteroate synthase, blocking para-aminobenzoic acid (PABA) incorporation into dihydrofolate, thereby inhibiting folate synthesis and bacterial growth.
One to two drops of SULF-10 ophthalmic solution (10% sulfacetamide sodium) instilled into the affected eye(s) every 2-3 hours initially, then decreasing frequency as infection resolves, up to 5-6 times daily.
Adults: 15 mg/kg orally every 6 hours for 10 days; maximum single dose 1 g.
None Documented
None Documented
Terminal elimination half-life is 7-12 hours in adults with normal renal function; prolonged in renal impairment
Expected ~6-9 hours based on related sulfacetamide; however, no specific data for SULFACEL-15. Clinical context: prolonged in renal impairment.
Renal excretion of unchanged drug and acetylated metabolites: ~85-90%; biliary/fecal: ~10-15%
Renal: ~85-90% unchanged; Biliary/Fecal: ~5-10% (metabolites and unchanged drug); ~5% eliminated via feces following biliary secretion.
Category C
Category C
Antibiotic (Sulfonamide)
Antibiotic (Sulfonamide)